Navigation Links
Sutro Biopharma Closes $26 Million Financing, Expands Development of Novel Immuno-Oncology Products
Date:12/11/2013

SAN FRANCISCO, Dec. 11, 2013 /PRNewswire/ -- Sutro Biopharma today announced that the company has secured $26 million in a Series D financing. The additional financing will fund the expansion of Sutro's proprietary immuno-oncology product pipeline.  Sutro is developing a new generation of protein therapeutics, including next-generation antibody drug conjugates and bispecific antibodies, utilizing the company's cell-free protein synthesis technology.

The financing closed in December 2013 and was led by Sutro's existing investors: Alta Partners, Amgen Ventures, Celgene Corporation, Lilly Ventures, Skyline Ventures and SV Life Sciences. Sutro has raised over $90 million since its founding in 2003.

"Our ability to accelerate the development of our immuno-oncology portfolio is now in hand. This successful financing further demonstrates the enthusiasm of our investors in Sutro and is a tremendous validation of our emerging product pipeline together with our broad technology platform. Sutro is an emerging leader in the rapid development of novel and differentiated products targeting immuno-oncology pathways," said William Newell, chief executive officer of Sutro Biopharma. "We will continue to advance candidates that leverage the immune system's natural ability to fight cancer, with the goal of establishing next generation immuno-oncology products that will transform cancer therapy for physicians and patients."  

About Sutro Biopharma

Sutro Biopharma, located in South San Francisco, is developing a new generation of antibody drug conjugate therapeutics and bifunctional antibody-based therapeutics for targeted cancer therapies. These therapeutics will significantly extend the clinical impact of current oncology therapeutic approaches and are beyond what can be envisioned with current, cell-based expression technologies. Sutro's biochemical synthesis technology, which underpins these therapeutics, allows the rapid and systematic exploration of many protein drug variants to identify drug candidates. Once the product candidates are identified, production can be rapidly and predictably scaled up to commercial levels. Sutro has established a Good Manufacturing Practice (cGMP) facility for the production of clinical supplies of materials using its biochemical protein synthesis platform. Sutro has formed multiple partnerships with biopharma companies utilizing its technology, including a collaboration with Celgene Corporation to design and develop novel antibody drug conjugates and bispecific antibodies as well as to manufacture a proprietary Celgene antibody.

For more information, visit www.sutrobio.com.

Media Contact:
Martina Schwarzkopf, Ph.D.
Russo Partners
(212) 845-4292
(347) 591-8785 (mobile)
martina.schwarzkopf@russopartnersllc.com


'/>"/>
SOURCE Sutro Biopharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. PDL BioPharma Provides Fourth Quarter 2013 Revenue Guidance of $109 Million
2. Array BioPharma Provides Clinical Update On ARRY-614 For Myelodysplastic Syndromes At The 2013 American Society Of Hematology Meeting
3. Array BioPharma Provides Clinical Update On Filanesib (ARRY-520) For Multiple Myeloma At The 2013 American Society of Hematology Meeting
4. Stocks Outperformed the Broader Markets: Facebook Inc, Twitter Inc, CF Industries Holdings, Green Mountain Coffee Roasters, Arca Biopharma
5. Corporate News, Acquisitions: Herbalife Ltd, 3D Systems Corporation, Federal National Mortgage Association, Galena Biopharma Inc, Oncomed Pharmaceuticals
6. Roundtable of Biopharma Industry Leaders Offers Insights to Market Access Challenges
7. Global Markets for Bioseparations for Biopharmaceutical Manufacturing to Jump to $6 Billion by 2018
8. Array BioPharma Announces Management Team Change
9. Rapid Delivery Program Product Portfolio Expands to Biopharmaceutical Injectable Market
10. MGB Biopharma Adds its Support to European Antibiotic Awareness Day
11. Array BioPharma To Present At The Jefferies 2013 Global Healthcare And Piper Jaffray 25th Annual Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Marks E-QURE , s 3 ... agreements in Israel and Argentina ... billion global market ... devices for the treatment of advanced wound care, announced today it signed a ... Colombia for the Company,s patented Bio-electrical Signal Therapy device ("BST Device"), ...
(Date:1/19/2017)... 2017  ViewRay, Inc. (Nasdaq: VRAY ... clinical MRI-guided radiation therapy system, announced today that it ... million through a private placement of its common ... financing and was joined by certain of ViewRay,s ... Venture Partners, and an additional new institutional investor, ...
(Date:1/19/2017)... , Jan. 18, 2017 The Global Therapy ... and access to partnering deals and agreements entered into ... in partnering deals - Top deals by value - ... development, technology type The report provides understanding and ... by the world,s leading healthcare companies. The report ...
Breaking Medicine Technology:
(Date:1/19/2017)... Angeles, CA (PRWEB) , ... January 18, 2017 , ... ... hazards while driving during a rain storm by slowing down and increasing the space ... on Fox 40. Los Angeles based car accident attorney Raymond R. Hassanlou notes that, ...
(Date:1/19/2017)... CA (PRWEB) , ... January 19, 2017 , ... Bill ... 2017 collaboration with the American Heart Association; “Howe” Healthy is Your Heart Drawing ... stay healthy and active. Each year, Bill Howe Plumbing, Heating & Air receives over ...
(Date:1/19/2017)... ... ... Connecticut Dermatology Group (CDG) is proud and excited to welcome back to ... Kim brings an extensive background in cutting-edge dermatology care and research to Connecticut’s largest ... Dr. Kim to the CDG team” said President and Managing Partner Dr. Steven A. ...
(Date:1/19/2017)... ... , ... The 21st Century Cures Act’s Impact on Medical Devices:, What You ... 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/21stcenturycures          , What do ... this year? , The passage of the act means devicemakers will be scrambling to ...
(Date:1/19/2017)... ... ... Sales Focus Inc. (SFI), a Maryland-based sales outsourcing company, announced today that ... 20 years SFI has been recognized as the world’s leader in Intelligent Sales Outsourcing ... US market. The new clients include: Panacea Pro, Campseekers, Contentmart, Stress Pal, Ariello, ...
Breaking Medicine News(10 mins):